文献速递前列腺癌

KEYLYNK-010:帕博利珠单抗联合奥拉帕利对比阿比特龙或恩扎卢胺治疗经治mCRPC的患者报告结局

Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2025-07-19

KEYLYNK-010 3期试验中,生物标志物未选择的经治转移性去势抵抗性前列腺癌患者随机接受帕博利珠单抗联合奥拉帕利或新型内分泌治疗。患者报告结局分析显示,两组至疼痛进展时间及15周时FACT-P、BPI-SF、EQ-5D VAS评分变化均无有意义的差异。

要点

  • 帕博利珠单抗联合奥拉帕利对比NHA未显著改善至疼痛进展时间。
  • 15周时FACT-P总分、BPI-SF及EQ-5D VAS评分变化两组间无有意义的差异。
  • 联合方案未对经治mCRPC患者的健康相关生活质量产生负面影响。

核心结论

  • 在生物标志物未选择的经治mCRPC患者中,帕博利珠单抗联合奥拉帕利对比NHA在健康相关生活质量或疾病相关症状评分方面未观察到有意义的差异。

研究设计与样本

  • 3期KEYLYNK-010试验的预设患者报告结局分析,患者按2:1随机接受帕博利珠单抗联合奥拉帕利或NHA(阿比特龙醋酸酯或恩扎卢胺)。
  • PRO分析人群共774例(帕博利珠单抗联合奥拉帕利组n=520,NHA组n=254),中位随访18.7个月(范围6.1-31.7)。

主要发现

  • 至疼痛进展时间两组无有意义的差异(中位13.5 vs 12.0个月;HR 0.95;95%CI 0.72-1.26)。
  • 从基线至第15周,FACT-P总分、BPI-SF及EQ-5D VAS评分的LSM变化在两组间无有意义的差异。

关键数值与推荐

  • PRO评估工具包括BPI-SF、FACT-P和EQ-5D-5L问卷。
  • PRO终点包括依据BPI-SF的至疼痛进展时间以及基线至第15周FACT-P总分、BPI-SF和EQ-5D VAS评分的LSM变化。

临床怎么用

  • 对于生物标志物未选择的经治mCRPC患者,帕博利珠单抗联合奥拉帕利未显著改善生活质量或症状评分,但亦未显示负面影响。

局限性

  • PRO分析未进行正式假设检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pembrolizumab plus olaparib did not significantly improve radiographic progression-free survival or overall survival versus a next-generation hormonal agent (NHA) in participants with biomarker-unselected, pretreated metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 KEYLYNK-010 trial. We present prespecified patient-reported outcomes (PROs) from KEYLYNK-010. METHODS: Participants were randomly assigned 2:1 to receive pembrolizumab plus olaparib or an NHA (abiraterone acetate or enzalutamide). PROs were evaluated using the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P), and EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaires. The PRO endpoints included time to pain progression (TTPP) as per BPI-SF and the least squares mean (LSM) change from baseline to week 15 in FACT-P total, BPI-SF, and EQ-5D visual analog scale (VAS) scores. KEY FINDINGS AND LIMITATIONS: The PRO analysis population included 774 participants (pembrolizumab plus olaparib, n = 520; NHA, n = 254). The median follow-up was 18.7 (range, 6.1-31.7) mo. No meaningful differences were observed in TTPP for pembrolizumab plus olaparib versus NHA (median: 13.5 vs 12.0 mo; hazard ratio 0.95; 95% confidence interval 0.72-1.26). From baseline to week 15, no meaningful LSM differences were observed between the treatment groups in FACT-P total, BPI-SF, and EQ-5D VAS scores. Limitations include no formal hypothesis testing. CONCLUSIONS AND CLINICAL IMPLICATIONS: No meaningful differences were observed in health-related quality of life (HRQoL) or disease-related symptom scores for pembrolizumab plus olaparib versus NHA in participants with biomarker-unselected, pretreated mCRPC. These findings suggest that pembrolizumab plus olaparib did not negatively impact HRQoL in participants with pretreated mCRPC. CLINICAL TRIAL REGISTRY: NCT03834519.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mehra N, Antonarakis ES, Park SH, et al. Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40685311. doi:10.1016/j.euo.2025.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。